Special Issue "Humanized Mice in Vaccinology: Opportunities and Challenges in 2021"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 535
Interests: humanized mice; viral persistence; viral pathogenesis; immunology
Interests: viral hemorrhagic fevers; immunology; dendritic cells; T cells
Special Issues, Collections and Topics in MDPI journals
Over the last decade, the use of mice harboring human cells, in particular human immune cells, has increased exponentially. The wide variety of available models with improved engraftment, mature, and functional human T and B cells and reduced graft vs. host disease has allowed one to study human-restricted pathogens and a variety of tumors as well as autoimmune diseases to an unprecedented detail. Importantly, some efforts have also been devoted to further develop models harboring not only human immune cells but also human peripheral cells from tissues with relevance in disease pathophysiology. A number of recent studies have also used humanized mice as in vivo platforms to test vaccine immunogenicity and protection.
In this Special Issue, we will discuss all aspects related to the use of humanized mice in vaccinology and discuss the opportunities and the challenges ahead.
Dr. César Muñoz-Fontela
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- humanized mice
- cancer vaccines
- dendritic cell vaccines
- T cells
- emerging viruses
- persistent viruses